Please login to the form below
Lyell Immunopharma
This page shows the latest Lyell Immunopharma news and features for those working in and with pharma, biotech and healthcare.
GSK pays $50m upfront to tap Immatics’ cell therapy platform
Last year, it signed a five-year collaboration with Lyell Immunopharma that is also aimed at the development of cell therapies for solid tumours. ... Lyell’s technology will be used to improve GSK’s cell therapy candidates, including GSK3377794,
Latest news
More from news
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- New Playbook Alert: Virtual Patient Engagement
- AbbVie to expand solid tumour portfolio with $10bn ImmunoGen acquisition
- UK Biobank reveals new data from world's largest genetic project
- New study finds dose of Mavenclad treatment could predict MS relapse risk
- Astellas shares positive 24-week results for non-hormonal menopause drug fezolinetant
- GSK global survey reveals misunderstandings about shingles in adults
No results were found
PMHub
Genetic Digital
We guide healthcare and life sciences organisations through digital transformation. Simplifying the complex world of tech and marketing, we create...
Latest intelligence
- New Playbook Alert: Virtual Patient Engagement
- ...
- Millennials: the wellness generation
- Looking at the results from a global healthcare research study focusing on the patients of the future...
- The problem with clinical trials (and how virtual insight-gathering can help)
- While still the gold standard of research, clinical trials are often riddled with issues that limit their applicability to broader populations or delay market access....
